U.S. President Donald Trump expressed confidence on Wednesday that China will soon impose the death penalty for fentanyl manufacturing and trafficking, signaling renewed optimism for a bilateral crackdown on the opioid crisis. Speaking ahead of signing the HALT Fentanyl Act, Trump emphasized collaboration with Beijing to halt the flow of synthetic opioids, which have claimed over 450,000 American lives in the past decade.
Fentanyl, a powerful synthetic opioid, remains a top cause of overdose deaths in the U.S., and Washington continues to pressure Beijing to tighten control over precursor chemicals exported from China. Trump’s remarks follow a series of recent moves aimed at reining in the deadly drug trade, including the February imposition of 20% tariffs on Chinese goods linked to fentanyl-related issues.
“I think China’s going to go from doing nothing to issuing the death penalty for those producing fentanyl and sending it here,” Trump told reporters. He added that talks with Chinese leader Xi Jinping were progressing and that Beijing was taking “big steps” in response.
In recent weeks, China has added two more fentanyl precursors—4-piperidone and 1-boc-4-piperidone—to its list of controlled substances. Authorities have also ramped up enforcement, seizing over 2 tons of drugs and arresting 262 individuals for trafficking. Over 1,300 prosecutions and 700 arrests for drug-related money laundering have been reported this year, showing a 2.1% increase from last year.
China, however, has pushed back on U.S. demands to publicize its efforts prominently and has accused Washington of politicizing the fentanyl issue. Still, Trump’s latest remarks suggest a possible breakthrough in cooperation as both nations grapple with rising overdose deaths and escalating tensions.


Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Trump Signs “America First Arms Transfer Strategy” to Prioritize U.S. Weapons Sales
Trump to Announce New Federal Reserve Chair Pick as Powell Replacement Looms
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
Ohio Man Indicted for Alleged Threat Against Vice President JD Vance, Faces Additional Federal Charges
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
Trump Orders DHS to Avoid Protests in Democratic Cities Unless Federal Assets Are Threatened
Trump Administration Sued Over Suspension of Critical Hudson River Tunnel Funding
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Trump Allegedly Sought Airport, Penn Station Renaming in Exchange for Hudson River Tunnel Funding
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster
Trump Proposes Two-Year Shutdown of Kennedy Center Amid Ongoing Turmoil
U.S. Justice Department Removes DHS Lawyer After Blunt Remarks in Minnesota Immigration Court 



